Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens

Nicola Di Renzo, MD, Maurizio Musso, MD, Rosanna Scimè, MD, Giuseppe Milone, MD PhD, Tommasina Perrone, MD, Clara De Risi, MD, Domenico Pastore, MD PhD, Attilio Guarini, MD, Andrea Mengarelli, MD, Fabio Benedetti, MD, Patrizio Mazza, MD, Vera Capria, MD, Patrizia Chiusolo, Luca Cupelli, MD, Vincenzo Federico, MD, Valentina Bozzoli, PhD MD, Anna Rita Messa, Giorgina Specchia, MD

Blood (2019) 134 (Supplement_1): 1974.

https://doi.org/10.1182/blood-2019-125071

Published: 2019

Journal Articles

Efficacy and Safety Of Melphalan and Prednisone In Combination With Thalidomide, Bortezomib Or Lenalidomide In Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients: A Single Center Experience

Fabiana Gentilini, MD, Vincenzo Federico, MD, Eleonora Russo, MD, Paola Finsinger, MD, Roberto Ricci, Patrizia Del Bianco, Francesca Prestanicola, Moira Cappelloni, Maria Letizia Vallone, Robin Foa, MD, Maria Teresa Petrucci, MD

Blood (2013) 122 (21): 5375.

https://doi.org/10.1182/blood.V122.21.5375.5375

Published: 2013

Journal Articles

Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age

Blood (2013) 122 (21): 539.

https://doi.org/10.1182/blood.V122.21.539.539

Published: 2013

Journal Articles

Clinical Characteristics and Predictive Factors of Peripheral Neurophaty in Multiple Myeloma Patients Treated with Bortezomib and/or Imids

Vincenzo Federico, MD, Russo Eleonora, MD, PhD, Andrea Truini, MD, Anna Levi, MD, PhD, Fabiana Gentilini, MD, Giulia Biagioli, Caterina Leoni, MD, Robin Foà, MD, Maria Teresa Petrucci, MD

Blood (2012) 120 (21): 4056.

https://doi.org/10.1182/blood.V120.21.4056.4056

Published: 2012

Journal Articles

Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.

Giacomo Salvatore Morano, Caterina Mercanti, Vincenzo Federico, MD, Angela Matturro, Alessandra Micozzi, Roberto Latagliata, MD, Massimo Breccia, Corrado Girmenia, Gregorio Antonio Brunetti, Paola Berneschi, Massimo Giampaoletti, Robin Foà, Giuliana Alimena

Blood (2009) 114 (22): 4545.

https://doi.org/10.1182/blood.V114.22.4545.4545

Published: 2009

Journal Articles

A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients.

Federica Cavallo, MD, Alessandra Larocca, MD, Maria Teresa Petrucci, MD, Vincenzo Federico, MD, Antonietta Pia Falcone, MD, Grazia Sanpaolo, MD, Letizia Canepa, MD, Monica Crugnola, MD, Mario Boccadoro, MD, Antonio Palumbo, MD

Blood (2009) 114 (22): 2864.

https://doi.org/10.1182/blood.V114.22.2864.2864

Published: 2009

Journal Articles

IgG and IgA Monoclonal Gammopathies of Undetermined Significance (MGUS) at Low Risk of Evolution: Proposal and Validation of a Prognostic Scoring System

Francesca Gaia Rossi, MD, Luigi Marcheselli, Maria Teresa Petrucci, MD, Davide Rossi, Vincenzo Callea, MD, Andrea Guffanti, MD, Marianna De Muro, MD, Vincenzo Federico, MD, Anna Baraldi, M.D., Pellegrino Musto, MD, Andrea Bacigalupo, MD, Gianluca Gaidano, Maria Goldaniga, MD, Giuseppe Avvisati, Giorgio Lambertenghi Deliliers, MD, Luca Baldini, MD

Blood (2008) 112 (11): 5136.

https://doi.org/10.1182/blood.V112.11.5136.5136

Published: 2008

Journal Articles

Neuropathy in Multiple Myeloma Patients Treated with Bortezomib: A Multicenter Experience.

Tommaso Caravita, MD, Maria Teresa Petrucci, MD, Alessandra Spagnoli, Agostina Siniscalchi, MD, Massimo Offidani, MD, Vincenzo Federico, MD, Patrizia Falco, MD, Manuela Rizzo, MD, Antonio Palumbo, MD, Paolo de Fabritiis, MD

Blood (2007) 110 (11): 4823.

https://doi.org/10.1182/blood.V110.11.4823.4823

Published: 2007

Journal Articles

Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.

Maria Rosaria Ricciardi, PhD, Elisabetta Calabrese, MD, Fabiana De Cave, PhD, Sara Santinelli, Paola Bergamo, Samantha Decandia, PhD, Chiara Gregorj, PhD, Vincenzo Federico, MD, Michele Milella, MD, Robert Foa, MD, Agostino Tafuri, MD, Maria Teresa Petrucci, MD

Blood (2007) 110 (11): 4782.

https://doi.org/10.1182/blood.V110.11.4782.4782

Published: 2007

NARROW

Efficacy and Safety Of Melphalan and Prednisone In Combination With Thalidomide, Bortezomib Or Lenalidomide In Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients: A Single Center Experience

Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age

Clinical Characteristics and Predictive Factors of Peripheral Neurophaty in Multiple Myeloma Patients Treated with Bortezomib and/or Imids

Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.

A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients.

IgG and IgA Monoclonal Gammopathies of Undetermined Significance (MGUS) at Low Risk of Evolution: Proposal and Validation of a Prognostic Scoring System

Neuropathy in Multiple Myeloma Patients Treated with Bortezomib: A Multicenter Experience.

Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only